Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
5
×
Tags
life sciences
national blog main
biotech
boston blog main
boston top stories
clinical trials
deals
fda
national top stories
alexion pharmaceuticals
alnylam pharmaceuticals
boston
drugs
hepatitis b
new york blog main
patisiran
san diego blog main
san diego top stories
startups
achaogen
adams street partners
akcea therapeutics
amyotrophic lateral sclerosis (als)
antibiotics
anylam pharmaceuticals
autoimmune disorders
beijing
beta lactamase inhibitor
biomedical advanced research and development authority (barda)
boehringer ingelheim
brii bio
brii biosciences
cardiomyopathy
china
complement system
dicerna pharamceuticals
drug resistance
generalized myasthenia gravis
glaxosmithkline
gsk
What
disease
5
×
drug
5
×
medicines
5
×
year
hepatitis
infectious
pharma
pharmaceuticals
adds
ago
akcea
alliance
alnylam
alternative
amyloidosis
approved
areas
attr
autoimmune
available
bacteria
battle
biopharma
biosciences
bio’s
brii
business
candidate
caught
causing
company
deal
debilitating
dicerna
earlier
exited
expensive
eye
fda
fighting
Language
unset
Current search:
medicines
×
photo
×
disease
×
drug
×
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections